Robo1 expression in breast cancer and its relationship to brain metastasis.
- Author:
Jing WANG
1
;
Le WANG
;
Fang-fang LIU
;
Yong-jie MA
;
Li FU
;
Wen-liang LI
;
Feng GU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Age Factors; Aged; Brain Neoplasms; secondary; Breast Neoplasms; metabolism; pathology; surgery; Carcinoma, Ductal, Breast; metabolism; secondary; surgery; Carcinoma, Intraductal, Noninfiltrating; metabolism; secondary; surgery; Female; Fibroadenoma; metabolism; Follow-Up Studies; Humans; Middle Aged; Nerve Tissue Proteins; metabolism; Receptors, Immunologic; metabolism; Survival Rate
- From: Chinese Journal of Oncology 2011;33(6):447-451
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo detect the expression of Robo1 in different breast tumors and its association with the breast cancer brain metastasis.
METHODSLabelled streptavidin-biotin (LSAB) staining was used to examine the Robo1 expression in specimens from 24 cases of invasive ductal carcinoma (IDC) with brain metastasis, 71 cases of IDC without brain metastasis, 22 cases of ductal carcinoma in situ (DCIS) and 23 cases of fibroadenoma.
RESULTSThe expression pattern of Robo1 in DCIS (59.1%) and IDC (45.3%) was significantly lower than that in adenofibroma (87.0%, P < 0.05). The expression of Robo1 in IDC with brain metastasis (12.5%) was significantly lower than that in IDC without brain metastasis (56.3%, P < 0.05). The expression of Robo1 was much higher in more than 50 year-old-group (57.8%) than that in less than 50 year-old-group (34.0%) of IDC patients. The overall survival time in patients with the Robo1 negative expression was significantly shorter than those with positive expression (P < 0.05). No correlation was found between the Robo1 expression and the tumor size, lymph node metastasis, pathologic stage, histological grade and clinical stage (P > 0.05).
CONCLUSIONSThe Robo1 expression correlates negatively with IDC brain metastasis, and correlates positively with the age and prognosis of IDC patients. Robo1 may be applied as a marker in evaluation of the IDC prognosis and brain metastasis.
